Brevan Howard Capital Management LP Acquires 19,890 Shares of Haemonetics Co. (NYSE:HAE)

Brevan Howard Capital Management LP increased its holdings in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 404.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,810 shares of the medical instruments supplier's stock after purchasing an additional 19,890 shares during the period. Brevan Howard Capital Management LP's holdings in Haemonetics were worth $1,937,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in HAE. TD Waterhouse Canada Inc. purchased a new position in shares of Haemonetics in the 4th quarter valued at about $25,000. Covestor Ltd increased its holdings in Haemonetics by 146.8% during the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock valued at $58,000 after acquiring an additional 439 shares in the last quarter. Whittier Trust Co. purchased a new position in Haemonetics during the 4th quarter valued at about $62,000. Parkside Financial Bank & Trust increased its holdings in Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock valued at $92,000 after acquiring an additional 240 shares in the last quarter. Finally, AlphaQuest LLC grew its holdings in shares of Haemonetics by 36,520.0% during the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock worth $143,000 after buying an additional 1,826 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

Haemonetics Trading Up 1.8%

Haemonetics stock traded up $1.21 during trading hours on Monday, reaching $69.40. 147,088 shares of the company's stock traded hands, compared to its average volume of 692,877. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. Haemonetics Co. has a fifty-two week low of $55.30 and a fifty-two week high of $97.97. The firm has a market capitalization of $3.49 billion, a price-to-earnings ratio of 27.31, a PEG ratio of 1.11 and a beta of 0.32. The firm's 50 day moving average is $62.75 and its 200-day moving average is $71.36.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating analysts' consensus estimates of $1.22 by $0.02. The business had revenue of $330.60 million for the quarter, compared to the consensus estimate of $329.38 million. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Haemonetics's revenue for the quarter was down 3.5% on a year-over-year basis. During the same period last year, the company posted $0.90 EPS. On average, analysts predict that Haemonetics Co. will post 4.55 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Raymond James reaffirmed a "strong-buy" rating and issued a $105.00 target price (down previously from $115.00) on shares of Haemonetics in a research report on Friday. Needham & Company LLC lowered their target price on shares of Haemonetics from $104.00 to $84.00 and set a "buy" rating on the stock in a research note on Thursday. Barrington Research lowered their target price on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a research note on Friday, February 7th. StockNews.com upgraded shares of Haemonetics from a "hold" rating to a "buy" rating in a report on Monday, May 5th. Finally, JMP Securities reduced their price objective on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a research note on Friday, February 7th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Haemonetics presently has an average rating of "Moderate Buy" and an average price target of $97.89.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.